Posts Tagged ‘inv:BDC-Capital’
Protiva, a Vancouver, B.C.-based developer of drugs based on the new technology of RNA interference, raised $3.3 million in debenture financing. Investors included GrowthWorks Capital, BDC Capital, the Canadian Medical Discoveries Fund and Kinetic Capital.
Protiva is currently embroiled in litigation against two other biotechs, including Sirna Therapeutics, another RNAi company acquired by Merck last December, and Tekmira Pharmaceuticals.
Top Stories
- How badly could a recession hurt cleantech? ...
- Google prepping special iPhone ads?
- Stock market swings wildly -- plunges, then ...
- Orkut on the iPhone — a Brazilian ...
- Will Condé Nast close Portfolio? Magazines stay ...
Recent Guest Columnists
- William Quigley
Remaining objective when fear is in the air - Todd Kimmel
What to expect from cleantech in the downturn - Lee Hower
Platforms and developers, part three: What platforms like Facebook can do to expand the developer ecosystem
Job Board
- Product Manager
at True Knowledge (Cambridge, Cambridgeshire, UK) - Interactive Production Designer
at EyeWonder, Inc (233 Peachtree Street Atlanta, GA 30303) - Alliance Marketing Consultant BP
at Sun Microsystems (MENLO PARK, CA) - More Jobs » | Post a Job »
Links
Venturebeat Writers
- Matt Marshall, Editor-in-Chief
- Dean Takahashi, Lead Writer, DigitalMedia
- Eric Eldon, Editor, DigitalMedia
- MG Siegler, Writer, DigitalMedia
- Anthony Ha, Writer, VentureBeat
- Chris Morrison, Writer, CleanTech
- For advertising, contact .
- Log in